# Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome

> **NCT01160666** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 20 (actual)

## Conditions studied

- Sjögren's Syndrome

## Interventions

- **DRUG:** Belimumab

## Key facts

- **NCT ID:** NCT01160666
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2011-12
- **Final completion:** 2012-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2012-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01160666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01160666, "Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01160666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*